IN2013MU02145A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02145A
IN2013MU02145A IN2145MU2013A IN2013MU02145A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A IN 2145MU2013 A IN2145MU2013 A IN 2145MU2013A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A
Authority
IN
India
Prior art keywords
monoclonal antibody
purification
provides
desired monoclonal
purity
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjay Bandyopadhyay
Sanjeev Kumar Mendiratta
Avanish Kumar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51655799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2013MU02145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to TW103121726A priority Critical patent/TWI596107B/zh
Priority to ARP140102380A priority patent/AR096713A1/es
Priority to EP14777867.4A priority patent/EP3013849B1/en
Priority to EA201592192A priority patent/EA201592192A1/ru
Priority to CA2911874A priority patent/CA2911874A1/en
Priority to BR112015031196A priority patent/BR112015031196A2/pt
Priority to MX2015016586A priority patent/MX350610B/es
Priority to HK16105366.7A priority patent/HK1217344A1/zh
Priority to JP2015563045A priority patent/JP6039828B2/ja
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to KR1020157035759A priority patent/KR101683415B1/ko
Priority to SG11201509502XA priority patent/SG11201509502XA/en
Priority to US14/895,432 priority patent/US9708365B2/en
Priority to PCT/IN2014/000421 priority patent/WO2014207763A1/en
Priority to NZ714079A priority patent/NZ714079A/en
Priority to IN2145MU2013 priority patent/IN2013MU02145A/en
Priority to CN201480031532.XA priority patent/CN105263947A/zh
Priority to AU2014300486A priority patent/AU2014300486B2/en
Publication of IN2013MU02145A publication Critical patent/IN2013MU02145A/en
Priority to ZA2015/08258A priority patent/ZA201508258B/en
Priority to IL242649A priority patent/IL242649A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
IN2145MU2013 2013-06-25 2014-06-25 IN2013MU02145A (enrdf_load_stackoverflow)

Priority Applications (19)

Application Number Priority Date Filing Date Title
TW103121726A TWI596107B (zh) 2013-06-25 2014-06-24 單株抗體之新穎純化方法
ARP140102380A AR096713A1 (es) 2013-06-25 2014-06-24 Proceso de purificación para anticuerpos monoclonales
AU2014300486A AU2014300486B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
SG11201509502XA SG11201509502XA (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
CA2911874A CA2911874A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
BR112015031196A BR112015031196A2 (pt) 2013-06-25 2014-06-25 “processo de purificação de anticorpo monoclonal”
MX2015016586A MX350610B (es) 2013-06-25 2014-06-25 Proceso para la purificacion de anticuerpos monoclonales.
HK16105366.7A HK1217344A1 (zh) 2013-06-25 2014-06-25 单克隆抗体的纯化工序
JP2015563045A JP6039828B2 (ja) 2013-06-25 2014-06-25 モノクローナル抗体の精製方法
EP14777867.4A EP3013849B1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
KR1020157035759A KR101683415B1 (ko) 2013-06-25 2014-06-25 단일클론항체에 대한 정제 방법
EA201592192A EA201592192A1 (ru) 2013-06-25 2014-06-25 Способ очистки моноклональных антител
US14/895,432 US9708365B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
PCT/IN2014/000421 WO2014207763A1 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
NZ714079A NZ714079A (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
IN2145MU2013 IN2013MU02145A (enrdf_load_stackoverflow) 2013-06-25 2014-06-25
CN201480031532.XA CN105263947A (zh) 2013-06-25 2014-06-25 单克隆抗体的纯化工艺
ZA2015/08258A ZA201508258B (en) 2013-06-25 2015-11-09 Purification process for monoclonal antibodies
IL242649A IL242649A (en) 2013-06-25 2015-11-18 Purification process of monoclonal antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2145MU2013 IN2013MU02145A (enrdf_load_stackoverflow) 2013-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
IN2013MU02145A true IN2013MU02145A (enrdf_load_stackoverflow) 2015-06-05

Family

ID=51655799

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2145MU2013 IN2013MU02145A (enrdf_load_stackoverflow) 2013-06-25 2014-06-25

Country Status (19)

Country Link
US (1) US9708365B2 (enrdf_load_stackoverflow)
EP (1) EP3013849B1 (enrdf_load_stackoverflow)
JP (1) JP6039828B2 (enrdf_load_stackoverflow)
KR (1) KR101683415B1 (enrdf_load_stackoverflow)
CN (1) CN105263947A (enrdf_load_stackoverflow)
AR (1) AR096713A1 (enrdf_load_stackoverflow)
AU (1) AU2014300486B2 (enrdf_load_stackoverflow)
BR (1) BR112015031196A2 (enrdf_load_stackoverflow)
CA (1) CA2911874A1 (enrdf_load_stackoverflow)
EA (1) EA201592192A1 (enrdf_load_stackoverflow)
HK (1) HK1217344A1 (enrdf_load_stackoverflow)
IL (1) IL242649A (enrdf_load_stackoverflow)
IN (1) IN2013MU02145A (enrdf_load_stackoverflow)
MX (1) MX350610B (enrdf_load_stackoverflow)
NZ (1) NZ714079A (enrdf_load_stackoverflow)
SG (1) SG11201509502XA (enrdf_load_stackoverflow)
TW (1) TWI596107B (enrdf_load_stackoverflow)
WO (1) WO2014207763A1 (enrdf_load_stackoverflow)
ZA (1) ZA201508258B (enrdf_load_stackoverflow)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH088818Y2 (ja) 1989-12-21 1996-03-13 株式会社イナックス タイル用捺印装置
TWI398554B (zh) * 2010-07-29 2013-06-11 Zhen Ding Technology Co Ltd 電鍍裝置
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
US10695693B2 (en) * 2015-03-13 2020-06-30 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
SI3337817T1 (sl) 2015-08-21 2021-12-31 F. Hoffmann - La Roche Ag Postopek za redukcijo beljakovin gostiteljske celice pri afinitetni kromatografiji
EP3337812B1 (en) * 2015-08-21 2021-04-28 F. Hoffmann-La Roche AG Method for the reduction of host cell proteins in affinity chromatography
JP7084301B2 (ja) * 2015-08-21 2022-06-14 エフ．ホフマン－ラ ロシュ アーゲー 低伝導率洗浄緩衝液を用いたアフィニティークロマトグラフィー精製方法
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
JP2019529350A (ja) 2016-08-16 2019-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 混合物から個々の抗体を定量する方法
MX2019004316A (es) 2016-10-25 2019-08-05 Regeneron Pharma Metodos y sistemas para analisis de datos cromatograficos.
CA3039667A1 (en) 2016-10-28 2018-05-03 Merck Sharp & Dohme Corp. Purification process for removal of tyrosine sulfation antibody variants; purified compositions
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
EP3559027B1 (en) 2016-12-23 2022-06-01 Serum Institute Of India Private Limited Methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
AR111761A1 (es) * 2017-05-16 2019-08-14 Cj Healthcare Corp Un método para purificar un anticuerpo o un fragmento de anticuerpo de este usando cromatografía de afinidad
EP3431168A1 (en) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après couplage conjugué anticorps-médicament
JP7301043B2 (ja) 2017-09-19 2023-06-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 粒子の形成を低減する方法及びそれにより形成される組成物
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CN110128538B (zh) * 2018-02-09 2022-08-26 鲁南制药集团股份有限公司 一种纯化抗cd20人鼠嵌合单克隆抗体的方法
CN119881293A (zh) 2018-03-21 2025-04-25 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP4559485A3 (en) 2018-07-19 2025-08-06 Ichnos Sciences S.A. Liquid antibody formulation
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
WO2020084503A1 (en) 2018-10-26 2020-04-30 Cadila Healthcare Limited A composition comprising antibody with reduced level of basic variants thereof
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN111153993B (zh) * 2018-11-07 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗TNF-α单克隆抗体的制备方法
CN109336969B (zh) * 2018-11-09 2021-02-12 杭州奕安济世生物药业有限公司 一种抗体的纯化方法
CN111269316B (zh) * 2018-12-04 2024-06-28 正大天晴药业集团南京顺欣制药有限公司 抗her2单克隆抗体的纯化方法
WO2020153390A1 (ja) * 2019-01-23 2020-07-30 第一三共株式会社 活性炭材料を使用する工程を含む抗体精製方法
US20220411466A1 (en) * 2019-11-22 2022-12-29 Morphosys Ag Method to increase antibody yield during ion exchange chromatography
CN114929725A (zh) * 2020-01-08 2022-08-19 信达生物制药(苏州)有限公司 阿达木单抗纯化方法及其稳定组合物
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2022245306A1 (en) * 2021-05-20 2022-11-24 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Protein purification by affinity chromatography
US20240262890A1 (en) * 2021-07-27 2024-08-08 Ariel Scientific Innovations Ltd. Large scale purification of antibodies
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN115491328A (zh) * 2022-08-31 2022-12-20 深圳市卫光生物制品股份有限公司 一种大肠杆菌表达蛋白及其表达纯化方法
EP4335869A1 (en) 2022-09-07 2024-03-13 Bio T Biyoteknoloji Cozumleri Ve Uretim Anonim Resin and chromatography column that purifies antibodies with protease resistant small peptides
CN118725127A (zh) * 2024-07-11 2024-10-01 信立泰(苏州)药业有限公司 一种抗pcsk9单克隆抗体的分离纯化方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1308455B9 (en) 1998-05-06 2006-06-14 Genentech, Inc. A composition comprising anti-HER2 antibodies
KR20010043323A (ko) 1998-05-06 2001-05-25 제넨테크, 인크. 이온 교환 크로마토그래피에 의한 단백질 정제 방법
IL139609A (en) * 1998-06-01 2006-06-11 Genentech Inc Separation of polypeptides monomers
US20060257972A1 (en) 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
KR101660575B1 (ko) * 2005-03-11 2016-09-27 와이어쓰 엘엘씨 약한 분배성 크로마토그래피법
CN104926938B (zh) 2005-06-17 2019-06-04 惠氏有限责任公司 纯化含Fc区蛋白的方法
WO2007109163A2 (en) 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
CN103509116A (zh) 2006-04-05 2014-01-15 艾伯维生物技术有限公司 抗体纯化
WO2008031020A2 (en) 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
CA2702637A1 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
US20110166332A1 (en) 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
TWI515202B (zh) 2009-10-20 2016-01-01 艾伯維有限公司 利用蛋白質ａ親和性層析進行抗ｉｌ－１３抗體之分離及純化
EP2695889A1 (en) * 2009-12-29 2014-02-12 Dr. Reddy's Laboratories Limited Protein purification by ion exchange
US9284347B2 (en) 2010-01-22 2016-03-15 Boehringer Ingelheim International Gmbh Chromatographic method for purifying FC-containing proteins
CN102179237A (zh) * 2010-04-26 2011-09-14 无锡加莱克色谱科技有限公司 一种用于分离、提纯单克隆抗体和抗体球蛋白的亲和色谱填料及其制备方法
NZ608943A (en) 2010-10-11 2015-04-24 Abbvie Bahamas Ltd Processes for purification of proteins
CN103562145B (zh) 2010-12-06 2016-09-21 颇尔公司 生物制品的连续加工方法
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
WO2012176158A1 (en) * 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
WO2013066707A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Chromatography process for resolving heterogeneous antibody aggregates
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
LT2969099T (lt) * 2013-03-14 2018-09-10 Amgen Inc. Pratekėjusio ligando pašalinimas afininiame gryninime
AU2014303125A1 (en) * 2013-05-13 2015-11-12 Medimmune, Llc Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法

Also Published As

Publication number Publication date
SG11201509502XA (en) 2015-12-30
EP3013849B1 (en) 2017-09-13
US9708365B2 (en) 2017-07-18
AU2014300486B2 (en) 2016-06-30
MX350610B (es) 2017-09-11
KR20160003311A (ko) 2016-01-08
US20160115195A1 (en) 2016-04-28
JP6039828B2 (ja) 2016-12-07
WO2014207763A1 (en) 2014-12-31
HK1217344A1 (zh) 2017-01-06
NZ714079A (en) 2017-05-26
CA2911874A1 (en) 2014-12-31
CN105263947A (zh) 2016-01-20
KR101683415B1 (ko) 2016-12-06
EP3013849A1 (en) 2016-05-04
MX2015016586A (es) 2016-03-16
AU2014300486A1 (en) 2015-11-26
TW201512217A (zh) 2015-04-01
ZA201508258B (en) 2017-03-29
JP2016525500A (ja) 2016-08-25
TWI596107B (zh) 2017-08-21
EA201592192A1 (ru) 2016-07-29
IL242649A (en) 2016-03-31
BR112015031196A2 (pt) 2017-07-25
AR096713A1 (es) 2016-01-27

Similar Documents

Publication Publication Date Title
IN2013MU02145A (enrdf_load_stackoverflow)
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX368177B (es) Proceso continuo de múltiples etapas para purificar anticuerpos.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
MX2023015125A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
WO2011106750A3 (en) Method and apparatus for enhanced lifetime and performance of ion source in an ion implantation system
WO2019083318A3 (ko) 개선된 면역글로불린의 정제방법
PH12019502298A1 (en) Monoclonal antibody to pd-l1
WO2018162557A3 (en) Method for purifying proteins using silicate
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
EA201400273A1 (ru) Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
MX2016000181A (es) Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
MY197993A (en) Method for protein purification
SG11201802997WA (en) Affinity chromatography carrier and method for purifying biological substance
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
MX2015013182A (es) Purificacion analitica basada en la afinidad de compuestos bioterapeuticos para el control de bioprocesos.
EP3560956A3 (en) Methods of treating inflammatory diseases
MX2017013454A (es) Deteccion de moleculas de acido nucleico.
EP4239329A3 (en) Method and apparatus
MX2019011343A (es) Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
WO2015004686A3 (en) A process for purification of efavirenz and intermediates thereof using chromatographic methods